The drug is claimed to be the first and only oral MET inhibitor recommended to treat advanced NSCLC harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping
Padcev is indicated as a monotherapy to treat locally advanced or metastatic urothelial cancer adult patients who previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The regulatory
Led by Deerfield Management, the funding round saw participation from existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform backed by KKR,
Initially executed in 2017, the agreement grants exclusive rights to Kyowa Kirin for the development and commercialisation of Ardelyx’s tenapanor to treat cardiorenal diseases including hyperphosphatemia in Japan.
The clinical trial is designed for assessing GRC 54276’s tolerability and safety as a monotherapy, as well as in combination with checkpoint inhibitors in these patients. GRC 54276
HBM7022 has been produced from HBM’s HCAb Based Immune Cell Engagers (HBICE) Platform. It crosslinks tumour and T cells by targeting a tumour-associated antigen (Claudin18.2) and CD3 that
This agreement is on developing and commercialising a gene therapy product based on ViGeneron’s engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD). As
A kinase inhibitor, vijoice is intended for the treatment of rare overgrowth conditions which are caused by the effects of PIK3CA mutations in adults and children aged two
Upon receiving approval, the human monoclonal antibody Dupixent will be the first medicine available in the US for the treatment of eosinophilic esophagitis (EoE). It is designed to
A recombinant humanized IgG4 monoclonal antibody, TAB009/JS009 is developed against human CD112R to treat advanced malignant tumours. CD112R, also known as Poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG), is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.